SPOTLIGHT: The top 5 deals of the first half of 2007

Deal-making continued at a blistering pace in the first half of 2007, as drug giants snapped up promising therapies from smaller developers in order to beef up their pipelines. Check out this report for a list of the companies that signed the biggest deals so far this year. List

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.